PDL BIOPHARMA, INC. - FORM 8-K - EX-99.2

Attached files

file	filename
8-K - PDL BIOPHARMA, INC.	v195765_8k.htm
EX-99.1 - PDL BIOPHARMA, INC.	v195765_ex99-1.htm

Reported Net Sales Revenue by Product ($ in 000's) *

Avastin	Q1		Q2		Q3		Q4		Total
2010		1,586,093		1,596,892		1,594,707				4,777,692
2009		1,345,487		1,295,536		1,439,730		1,514,053		5,594,806
2008		980,715		1,084,930		1,180,427		1,239,382		4,485,454
2007		678,068		746,587		797,013		875,084		3,096,752
2006		439,318		516,052		570,551		592,897		2,118,817

Herceptin	Q1		Q2		Q3		Q4		Total
2010		1,337,732		1,349,512		1,300,934				3,988,178
2009		1,210,268		1,133,993		1,226,435		1,278,626		4,849,323
2008		1,105,426		1,195,215		1,211,982		1,186,806		4,699,428
2007		891,761		949,556		979,602		1,015,033		3,835,952
2006		529,585		659,719		761,099		803,576		2,753,979

Lucentis	Q1		Q2		Q3		Q4		Total
2010		759,965		698,890		745,376				2,204,231
2009		462,103		469,736		555,296		615,212		2,102,347
2008		363,615		393,682		460,167		454,922		1,672,386
2007		224,820		219,579		299,995		322,300		1,066,695
2006		-		-		10,689		157,742		168,431

Xolair	Q1		Q2		Q3		Q4		Total
2010		240,904		225,878		251,055				717,836
2009		184,669		181,086		211,006		219,693		796,454
2008		137,875		169,521		177,179		183,753		668,329
2007		129,172		130,700		144,250		147,754		551,876
2006		95,241		99,354		112,608		118,002		425,204

Raptiva	Q1		Q2		Q3		Q4		Total
2010		-		14,224		-				14,224
2009		62,653		21,526		1,502		-		85,681
2008		55,541		57,601		66,992		65,216		245,349
2007		45,134		47,401		52,914		53,885		199,333
2006		32,672		35,458		39,610		41,353		149,093

Synagis	Q1		Q2		Q3		Q4		Total
2010		-		-		-				-
2009		571,486		623,951		57,271		105,314		1,358,021
2008		542,283		574,207		80,930		141,696		1,339,116
2007		478,388		548,227		53,586		139,736		1,219,936
2006		472,362		489,634		30,185		124,629		1,116,811

Tysabri	Q1		Q2		Q3		Q4		Total
2010		293,047		287,925		293,664				874,635
2009		221,854		229,993		257,240		285,481		994,569
2008		129,430		163,076		200,783		233,070		726,359
2007		30,468		48,715		71,972		94,521		245,675
2006		-		-		-		7,890		7,890

Actemra	Q1		Q2		Q3		Q4		Total
2010		52,908		5,405		10,493				68,806
2009		19,504		17,920		30,313		39,888		107,627
2008		1,452		1,377		5,981		12,305		21,116
2007		2,388		873		1,071		1,137		5,470
2006		-		-		-		-		-

Mylotarg	Q1		Q2		Q3		Q4		Total
2010		8,500		8,658		8,142				25,300
2009		8,367		8,406		8,813		8,654		34,240
2008		8,978		8,050		8,225		8,140		33,393
2007		7,879		8,202		8,345		7,878		32,304
2006		8,832		9,084		8,874		16,081		42,871

* As reported to PDL by its licensees

Royalty Revenue by Product ($ in 000's) *

Avastin	Q1			Q2		Q3		Q4		Total
2010		16,870			44,765		29,989				91,624
2009		13,605			35,161		21,060		15,141		84,966
2008		9,957			30,480		19,574		12,394		72,405
2007		8,990			21,842		17,478		9,549		57,859
2006		10,438			15,572		15,405		12,536		53,952

Herceptin	Q1			Q2		Q3		Q4		Total
2010		23,402			38,555		27,952				89,909
2009		16,003			32,331		26,830		18,615		93,779
2008		14,092			34,383		28,122		20,282		96,880
2007		19,035			28,188		22,582		14,802		84,608
2006		15,142			19,716		21,557		20,354		76,769

Lucentis	Q1			Q2		Q3		Q4		Total
2010		7,220			19,091		10,841				37,151
2009		4,621			12,863		8,123		6,152		31,759
2008		3,636			11,060		7,631		4,549		26,876
2007		2,931			6,543		6,579		3,517		19,570
2006		-			-		289		3,335		3,624

Xolair	Q1			Q2		Q3		Q4		Total
2010		3,723			6,386		4,980				15,089
2009		2,665			5,082		4,085		3,722		15,553
2008		1,488			4,866		3,569		2,927		12,850
2007		1,684			3,942		3,332		2,184		11,142
2006		2,263			2,969		3,041		2,495		10,768

Raptiva	Q1			Q2		Q3		Q4		Total
2010		(150	)		142		-				(8	)
2009		477			589		22		150		1,238
2008		405			1,618		1,111		802		3,937
2007		588			1,246		1,160		738		3,733
2006		776			1,060		1,069		874		3,780

Synagis	Q1			Q2		Q3		Q4		Total
2010		-			-		-				-
2009		17,145			18,869		1,568		3,159		40,741
2008		16,268			17,376		2,278		4,251		40,173
2007		14,352			16,747		1,608		4,042		36,748
2006		14,171			14,689		831		3,664		33,354

Tysabri	Q1			Q2		Q3		Q4		Total
2010		8,791			8,788		8,735				26,314
2009		6,656			7,050		7,642		8,564		29,912
2008		3,883			5,042		5,949		6,992		21,866
2007		839			1,611		2,084		2,836		7,370
2006		-			-		-		237		237

Actemra	Q1			Q2		Q3		Q4		Total
2010		1,587			237		315				2,139
2009		585			537		909		1,197		3,228
2008		44			116		179		369		708
2007		32			326		32		34		425
2006		-			-		-		-		-

Mylotarg	Q1			Q2		Q3		Q4		Total
2010		366			153		285				804
2009		293			370		805		453		1,921
2008		314			132		288		209		943
2007		276			137		292		426		1,131
2006		309			168		311		568		1,355

* As reported to PDL by its licensees

Manufacturing Split - Genentech / Roche & Novartis *

Avastin	2009 - Q1			2009 - Q2			2009 - Q3			2009 - Q4			2010 - Q1			2010 - Q2			2010 - Q3
US Made & Sold		729,006			703,216			777,635			795,199			795,453			814,872			820,453
US Made & ex-US Sold		616,481			592,320			662,095			718,855			703,661			355,742			338,929
ex-US Made & Sold		-			-			-			-			86,979			426,277			435,325
Total		1,345,487			1,295,536			1,439,730			1,514,053			1,586,093			1,596,892			1,594,707
US Made & Sold		54	%		54	%		54	%		53	%		50	%		51	%		51	%
US Made & ex-US Sold		46	%		46	%		46	%		47	%		44	%		22	%		21	%
ex-US Made & Sold		0	%		0	%		0	%		0	%		5	%		27	%		27	%

Herceptin	2009 - Q1			2009 - Q2			2009 - Q3			2009 - Q4			2010 - Q1			2010 - Q2			2010 - Q3
US Made & Sold		344,808			347,932			391,401			386,654			394,883			406,222			410,563
US Made & ex-US Sold		670,459			440,821			256,693			608,046			372,146			312,792			306,085
ex-US Made & Sold		195,000			345,241			578,341			283,926			570,703			630,498			584,286
Total		1,210,268			1,133,993			1,226,435			1,278,626			1,337,732			1,349,512			1,300,934
US Made & Sold		28	%		31	%		32	%		30	%		30	%		30	%		32	%
US Made & ex-US Sold		55	%		39	%		21	%		48	%		28	%		23	%		24	%
ex-US Made & Sold		16	%		30	%		47	%		22	%		43	%		47	%		45	%

Lucentis	2009 - Q1			2009 - Q2			2009 - Q3			2009 - Q4			2010 - Q1			2010 - Q2			2010 - Q3
US Made & Sold		229,921			232,413			251,182			266,405			323,153			300,501			326,840
US Made & ex-US Sold		232,182			237,323			304,114			348,808			436,812			398,389			418,536
ex-US Made & Sold		-			-			-			-			-			-			-
Total		462,103			469,736			555,296			615,212			759,965			698,890			745,376
US Made & Sold		50	%		49	%		45	%		43	%		43	%		43	%		44	%
US Made & ex-US Sold		50	%		51	%		55	%		57	%		57	%		57	%		56	%
ex-US Made & Sold		0	%		0	%		0	%		0	%		0	%		0	%		0	%

Xolair	2009 - Q1			2009 - Q2			2009 - Q3			2009 - Q4			2010 - Q1			2010 - Q2			2010 - Q3
US Made & Sold		135,732			133,843			146,022			150,950			157,503			145,245			165,109
US Made & ex-US Sold		531			77			47			10			-			-			-
ex-US Made & Sold		48,406			47,166			64,937			68,733			83,401			80,632			85,945
Total		184,669			181,086			211,006			219,693			240,904			225,878			251,055
US Made & Sold		74	%		74	%		69	%		69	%		65	%		64	%		66	%
US Made & ex-US Sold		0	%		0	%		0	%		0	%		0	%		0	%		0	%
ex-US Made & Sold		26	%		26	%		31	%		31	%		35	%		36	%		34	%

Total	2009 - Q1			2009 - Q2			2009 - Q3			2009 - Q4			2010 - Q1			2010 - Q2			2010 - Q3
US Made & Sold		1,464,837			1,434,715			1,567,742			1,599,208			1,670,992			1,666,840			1,722,965
US Made & ex-US Sold		1,556,936			1,274,755			1,222,949			1,675,718			1,512,620			1,081,147			1,063,551
ex-US Made & Sold		243,406			392,407			643,279			352,659			741,083			1,137,407			1,105,556
Total		3,265,179			3,101,878			3,433,970			3,627,585			3,924,694			3,885,394			3,892,072
US Made & Sold		45	%		46	%		46	%		44	%		43	%		43	%		44	%
US Made & ex-US Sold		48	%		41	%		36	%		46	%		39	%		28	%		27	%
ex-US Made & Sold		7	%		13	%		19	%		10	%		19	%		29	%		28	%

* As reported to PDL by its licensees

PDL BIOPHARMA, INC. - FORM 8-K - EX-99.2 - September 1, 2010

Attached files

PDL BIOPHARMA, INC. Reports